PTLA - Alexion To Acquire Portola - What That Means
Alexion Pharmaceuticals (NASDAQ: ALXN) is a more than $20 billion company that has announced it is acquiring Portola Pharmaceuticals (NASDAQ: PTLA) for $1.45 billion. That represents an acquisition worth almost 8% of the company’s market capitalization. Given Alexion Pharmaceuticals' fairly small market capitalization, and already strong earnings power, this acquisition could mean significantly more shareholder returns.
Alexion Pharmaceuticals - Fierce Pharma
Acquisition Details
Alexion Pharmaceuticals is making a significant acquisition utilizing its portfolio of cash. That’s because the company is seeking to diversify away from Soliris, its blockbuster drug that makes up almost